EXD2 Protects Stressed Replication Forks and Is Required for Cell Viability in the Absence of BRCA1/2


To cite this version:


HAL Id: hal-03083184
https://hal.archives-ouvertes.fr/hal-03083184
Submitted on 18 Dec 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
EXD2 Protects Stressed Replication Forks and Is Required for Cell Viability in the Absence of BRCA1/2

Highlights
- EXD2 is required for cell survival in response to replicative stress
- EXD2 protects replication forks from over resection by counteracting fork reversal
- EXD2 is synthetic lethal with the deficiency in BRCA1/2 genes

Authors
Jadwiga Nieminuszczy, Ronan Broderick, Marina A. Bellani, ..., Sarantis Gagos, Michael M. Seidman, Wojciech Niedzwiedz

Correspondence
wojciech.niedzwiedz@icr.ac.uk

In Brief
Nieminuszczy et al. identify a key function of the EXD2 nuclease in DNA replication and alternative end-joining. EXD2 localizes to replication forks and promotes their stabilization by counteracting fork regression. Loss of EXD2 results in sensitivity to replicative inhibitors, degradation of regressed forks, and compromises survival of BRCA1/2-deficient tumors.
EXD2 Protects Stressed Replication Forks and Is Required for Cell Viability in the Absence of BRCA1/2

Jadwiga Nieminuszczy,1,8 Ronan Broderick,1,8 Marina A. Bellani,2 Elizabeth Smethurst,3 Rebekka A. Schwab,3,7 Veronica Cherdynshteva,4 Theodora Evmorfopoulou,4 Yea-Lih Lin,5 Michal Minczuk,6 Philippe Pasero,5 Sarantis Gagos,4 Michael M. Seidman,2 and Wojciech Niedzwiedz1,9,*

1The Institute of Cancer Research, London, UK
2Laboratory of Molecular Gerontology, National Institute on Aging, Baltimore, MD, USA
3Institute of Molecular Medicine, Oxford, UK
4Laboratory of Genetics, Biomedical Research Foundation of the Academy of Athens, Athens, Greece
5Institut de Génétique Humaine, CNRS, Université de Montpellier, Montpellier, France
6MRC Mitochondrial Biology Unit, University of Cambridge, Cambridge, UK
7Present address: Division of Structural Biology, Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
8These authors contributed equally
9Lead Contact
*Correspondence: wojciech.niedzwiedz@icr.ac.uk
https://doi.org/10.1016/j.molcel.2019.05.026

SUMMARY

Accurate DNA replication is essential to preserve genomic integrity and prevent chromosomal instability-associated diseases including cancer. Key to this process is the cell’s ability to stabilize and restart stalled replication forks. Here, we show that the EXD2 nuclease is essential to this process. EXD2 recruitment to stressed forks suppresses their degradation by restraining excessive fork regression. Accordingly, EXD2 deficiency leads to fork collapse, hypersensitivity to replication inhibitors, and genomic instability. Impeding fork regression by inactivation of SMARCA1 or removal of RECQ1’s inhibition in EXD2−/− cells restores efficient fork restart and genome stability. Moreover, purified EXD2 efficiently processes substrates mimicking regressed forks. Thus, this work identifies a mechanism underpinned by EXD2’s nuclease activity, by which cells balance fork regression with fork restoration to maintain genome stability. Interestingly, from a clinical perspective, we discover that EXD2’s depletion is synthetic lethal with mutations in BRCA1/2, implying a non-redundant role in replication fork protection.

INTRODUCTION

Faithful duplication of the genome during cell division ensures accurate transmission of genetic information to daughter cells. This process relies on the replication of the entire genomic DNA during S-phase by thousands of replication forks. However, replication fork stability is constantly challenged by damage to the DNA template or progression through chromosomal regions that are inherently difficult to replicate (Bhowmick and Hickson, 2017; Gaillard et al., 2015; Kolinjivadi et al., 2017a). These blockades can collapse replication forks, contributing to tumor progression by driving chromosomal instability (Burrell et al., 2013; Hills and Diffley, 2014; Jeggo et al., 2016; Kass et al., 2016; Zeman and Cimprich, 2014). To counteract this threat, cells possess mechanisms to protect stalled replication forks, the most important of which is the replication fork protection pathway. This surveillance pathway, underpinned by the ATR kinase, ensures inhibition of cell-cycle progression, suppression of late origin firing, and restart of stalled replication forks (Jackson and Bartek, 2009; Kass et al., 2016; O’Driscoll, 2012). Together, these events ensure the faithful completion of DNA synthesis (Cimprich and Cortez, 2008; Neelsen and Lopes, 2015; Zeman and Cimprich, 2014). The importance of these responses is highlighted by several cancer-predisposing human diseases caused by mutations in various proteins contributing to replication fork stability (e.g., Seckel, Bloom, Werner, or Fanconi anemia syndromes).

Recently, fork reversal has emerged as a key mechanism protecting stressed replication forks (Neelsen and Lopes, 2015; Ray Chaudhuri et al., 2012; Zeilweger et al., 2015). This process involves regression of the fork, mediated by several SNF2-family fork remodelers, and the formation of a 4-way junction. Once the blockade is removed, regressed forks remain capable of resuming DNA synthesis. The restart process is mediated by the RECQ1 helicase, which has the ability to migrate and resolve these 4-way structures (Berti et al., 2013; Neelsen and Lopes, 2015). Interestingly, in bacteria and yeast, a controlled nucleolytic processing of regressed nascent strands stabilizes stalled forks and prevents their reversal (Hu et al., 2012; Yeeles et al., 2013). Whether a similar mechanism exists in mammalian cells is currently unclear. Nevertheless, the ability to “resolve” regressed replication forks is crucial for genome stability, because the unregulated activity of fork remodelers induces degradation
of nascent DNA and drives chromosomal instability (Couch et al., 2013; Dungrawala et al., 2017; Thangavel et al., 2015).

Elegant work from several laboratories indicated that the BRCA1/2 proteins protect nascent DNA at reversed forks (Kolinjivadi et al., 2017b; Lemaçon et al., 2017; Mijic et al., 2017; Schlacher et al., 2011; Taglialatela et al., 2017). The fork protection function of BRCA1/2 is RAD51-dependent, as cells depleted for RAD51 or lacking the RAD51 stabilizing factor BOD1L, display extensive nascent DNA degradation (Hashimoto et al., 2010; Higgs et al., 2015; Schlacher et al., 2011). Fork protection also requires components of the Fanconi anemia pathway, which cooperate with BRCA1/2 in suppressing nascent DNA degradation (Schlacher et al., 2011). More recently, several nucleases (i.e., MRE11, DNA2, EXO1, and WRN) have also been implicated in supporting damaged forks (Iannascoli et al., 2015; Karanja et al., 2014; Lemaçon et al., 2017; Thangavel et al., 2015). Consequently, defective fork processing by these enzymes leads to fork collapse, increased genomic instability, and contributes to the development of chemotherapy resistance (Chaudhuri et al., 2016; Neelsen and Lopes, 2015).

Despite extensive research, it is not fully understood how cells maintain genome stability at sites of stalled DNA replication and how the different nucleases and fork remodelers function to balance fork regression with fork restart to restore the replication program. Because replication stress drives tumorigenesis and restoration of fork protection in cancer cells facilitates the development of chemotherapeutic resistance, it is crucial to understand these mechanisms (Berti and Vindigni, 2016; Kolinjivadi et al., 2017a; Yeeles et al., 2013).

Here, we show that the EXD2 nuclease, a protein recently shown to promote genome stability in Drosophila (Cox et al., 2007) and human cell lines (Biels et al., 2017; Broderick et al., 2016; Smogorzewska et al., 2010), is a component of the replication fork protection pathway. Accordingly, EXD2 is recruited to stalled replication forks and cells lacking EXD2 or expressing a nuclease-dead version of the protein display high levels of replication-associated genome instability. Mechanistically, we show that EXD2 acts to counteract fork reversal and this activity is critical for suppression of uncontrolled degradation of nascent DNA and efficient fork restart. In line with this, EXD2−/− cells accumulate regressed replication forks and restricting fork regression by silencing SMARCAL1 or removal of PARP1-dependent inhibition of RECQ1 suppresses their degradation and allows for efficient fork restart in these cells. Purified EXD2 can process synthetic fork-like structures in vitro, and in vivo its nuclease activity acts to suppress the collapse of terminally regressed forks. Unexpectedly, we also discover that depletion of EXD2 confers a synthetic lethal interaction with BRCA1/2, suggesting a non-redundant function between these repair factors. Taken together, our findings uncover a previously unknown role for EXD2 in the replication stress response and also identifies EXD2 as a potential druggable target for cancer therapy.

RESULTS

EXD2 Is Recruited to Replication Forks following Replication Stress

Recently, we have employed isolation of proteins on nascent DNA (iPOND) coupled with mass spectrometry to identify factors recruited to stalled replication forks (Higgs et al., 2015). This analysis identified EXD2, as a factor recruited to replication forks (Figure S1A). We confirmed these results by western blotting (Figure S1B) (Coquel et al., 2018). To test if EXD2 associates specifically with replication forks, we performed an iPOND analysis coupled with a thymidine-chase. This revealed that the abundance of EXD2 decreased upon the chase with thymidine (Figure 1A) as observed previously for PCNA (Sirbu et al., 2011). To further verify EXD2’s association with newly replicated DNA, we combined EdU labeling with the proximity-igation assay (PLA) to gauge the proximity of proteins with labeled nascent DNA (Higgs et al., 2015; Taglialatela et al., 2017) (Figures 1B and 1C). To this end, U2OS cells stably expressing GFP-EXD2 (Figure S1D) were labeled with EdU and subsequently treated with hydroxyurea (HU) followed by PLA to detect protein association with biotin-labeled nascent DNA. First, we validated this approach by testing the co-localization of MRE11 with nascent DNA after replication stress. As expected, MRE11 was significantly enriched following HU treatment (Figure 1C), consistent with its role at the stressed forks (Costanzo, 2011; Hashimoto et al., 2010; Taglialatela et al., 2017). Importantly, we could also readily detect nuclear PLA signal for EXD2 in cells treated with HU (Figure 1D), which was significantly enriched compared to untreated and control samples. To ascertain that this phenotype is not restricted to the GFP tag or its position, we repeated these experiments using U2OS cells expressing FLAG-tagged EXD2 (Broderick et al., 2016) and C-terminally GFP-tagged EXD2 (Figures S1E and S1F), confirming the specificity of its nuclear co-localization with stalled forks. Moreover, time-dependent analysis of EXD2 recruitment to stalled forks revealed similar kinetics to those of MRE11 (Figures S2A–S2D). Next, to gain further insight into the dynamics of EXD2 recruitment to DNA lesions, we employed laser micro-irradiation combined with live cell imaging (Suhasini et al., 2013). This analysis revealed that GFP-EXD2 is rapidly recruited to laser-generated DNA lesions.

Figure 1. EXD2 Is Recruited to Stressed Replication Forks

(A) Western blot of iPOND samples. Thymidine chase analysis illustrates that EXD2 specifically associates with the replisome. PCNA acts as a control.

(B) Schematic of the proximity ligation assay (PLA) employed to detect colocalization of target proteins with nascent DNA.

(C) Percentage of cells with MRE11/biotin PLA foci (mean ± SEM, n = 3 independent experiments, t test). Right: representative images of PLA foci (red), DAPI acts as a nuclear counterstain. Scale bar, 10 μm.

(D) Percentage of cells with GFP/biotin PLA foci (mean ± SEM, n = 3 independent experiments, t test) in U2OS control cells and U2OS cells expressing GFP-EXD2. Right: representative images of PLA foci (red), DAPI acts as a nuclear counterstain. Scale bar, 10 μm.

(E) Laser microirradiation induces rapid redistribution of GFP-EXD2 to damaged chromatin; representative images showing GFP-EXD2 accumulation at laser-generated DNA lesions. GFP-Ctip was used as a positive control. Scale bar, 10 μm.

(F) Quantification of GFP-EXD2 (left panel) and GFP-Ctip (right panel) recruitment kinetics (intensity versus time) to laser-generated DNA lesions (mean ± SE, n ≥ 10 cells from 2 independent experiments).
DNA damage, with faster kinetics than those of GFP-CtIP (Figures 1E and 1F; Video S1), underscoring its early role in the DNA repair processes. Taken together, this data suggest that EXD2 is rapidly recruited to damaged chromatin and associates with sites of DNA replication.

**EXD2 Promotes Global Replication Fork Dynamics in Response to Replicative Stress**

To shed light on the role of EXD2 during DNA replication, we analyzed the survival of EXD2−/− cells exposed to agents that impede fork progression. Loss of EXD2 sensitizes cells not only to MMC, CPT, and MMS as reported (Broderick et al., 2016; Smogorzewska et al., 2010) but also other drugs capable of blocking fork progression, i.e., cisplatin, gemcitabine, and HU (Figures 2A, S2E, and S2F), suggesting a general role in mitigating replicative stress.

To address the mechanism by which EXD2 promotes DNA replication, we used the DNA fiber assay to visualize individual replication forks. First, we quantified replication fork asymmetry in unchallenged cells (Schwab et al., 2015). We observed a significant increase in sister fork asymmetry in HeLa EXD2−/− cells (Figure 2B), suggesting increased rates of fork stalling or collapse. Consistently, transient exposure of EXD2-deficient cells to HU impeded replication fork dynamics (Figure 2C) as well as restart of stressed forks (Figure 2D). Moreover, forks that were able to recover DNA synthesis did so with a significant delay (Figure 2D). To determine the fate of stalled replication forks, we analyzed the formation of 53BP1 foci, a marker of dou-

**Loss of EXD2 Leads to Mitotic Abnormalities Associated with Under-Replicated DNA**

Failure to fully complete DNA replication leads to cells entering mitosis with under-replicated DNA, causing chromosome breakage and inhibiting cells’ ability to segregate chromosomes (Burrell et al., 2013). This can be visualized as formation of anaphase bridges, 53BP1 OPT domains in daughter cells, and formation of micronuclei (MN) (Harrigan et al., 2011; Lukas et al., 2011). In support of EXD2’s role in promoting genome duplication, EXD2-deficiency correlates with high levels of anaphase bridges or 53BP1 OPT domains (Figures 4A and 4B).

Additionally, the frequency of MN is also elevated by ~2-fold in EXD2−/− cells as compared to WT (Figure 4C). Importantly, only the WT protein, but not the nuclease-dead mutant, is capable of complementing these defects (Figures 4D–4F). Collectively, these data indicate that EXD2 promotes recovery of stressed forks thereby suppressing fork collapse and the generation of replication intermediates that may interfere with chromosomal segregation and drive genome instability.

**EXD2 Protects Replication Forks against Uncontrolled Degradation**

Recent work suggests that stressed replication forks undergo excessive nucleolytic degradation (Chaudhuri et al., 2016; Hashimoto et al., 2010; Karanja et al., 2014; Lachaud et al., 2015; Schlacher et al., 2011). This process drives genome instability and underpins the ability of cancer cells to become chemoresistant. Key players in this process are the BRCA1/2 proteins that inhibit MRE11 nuclelease-dependent fork resection by regulating RAD51 loading onto stalled forks (Chaudhuri et al., 2016; Kolijnvadi et al., 2017b; Lemaçon et al., 2017; Mijic et al., 2017; Pasero and Vindigni, 2017). To determine the mechanism by which EXD2 protects stressed forks, we tested if EXD2 loss impacts on fork resection by employing a modified DNA fiber protocol as described recently (Chaudhuri et al., 2016). Briefly, WT and EXD2-deficient HeLa cells were incubated with IdU and CldU and then exposed to HU. Strikingly, EXD2-deficient cells also displayed significantly elevated fork resection compared to WT cells, reflecting degradation of newly replicated DNA after fork arrest (Figure 5A, left panel). Importantly, this seems to be a general, non-cell line restricted phenotype, as we observed a similar response in U2OS EXD2−/− cells (Figure 5A, right panel). In line with EXD2’s role in protecting stalled forks, we also observed increased co-localization between EXD2 and the fork-protection factor BRCA1 upon replicative stress (Figure 5B).

Pathological degradation of unstable forks has been attributed to the deleterious activity of MRE11 (Chaudhuri et al., 2016; Kolijnvadi et al., 2017; Mijic et al., 2017; Schlacher et al., 2011). Because EXD2 functionally interacts with MRE11 during homology-mediated repair (Broderick et al., 2016), we asked if MRE11 can drive fork processing upon loss of EXD2. To test this, we employed mirin, an MRE11 inhibitor shown to block fork resection (Schlacher et al., 2011; Taglialetela et al., 2017). Strikingly, treatment with mirin reversed the excess fork degradation seen in EXD2−/− cells (Figure 5C). A similar result was achieved using small interfering RNA (siRNA) against MRE11 (Figures 5D and S3A). Because BRCA1/2 have been shown to prevent MRE11-dependent degradation of stressed forks by promoting RAD51 loading (Hashimoto et al., 2010; Schlacher et al., 2011), we considered the possibility that loss of EXD2 impairs recruitment or retention of RAD51 at nascent DNA. However, this does not seem to be the case, as we do not see any major change in the number of RAD51-dependent PLA foci at the sites of fork stalling in EXD2−/− cells in contrast to BRCA1 knockdown (Figure S3B). Consistently, the level of BRCA1 loading at the vicinity of stalled forks is also similar between WT and EXD2−/− cells (Figure S3C). Finally, and in contrast to BRCA1 deficiency (Taglialetela et al., 2017), we also did not observe an increased recruitment of MRE11 to stalled forks in EXD2−/− cells.
Figure 2. EXD2 Promotes Global Replication Fork Dynamics in Response to Replicative Stress

(A) Survival of HeLa control and HeLa EXD2<sup>−/−</sup> cells treated with the indicated doses of cisplatin, gemcitabine, mitomycin C, or hydroxyurea (mean ± SEM, n = 3 independent experiments).

(B) Boxplot of CldU tract length ratios of associated sister forks from HeLa WT and EXD2<sup>−/−</sup> cells. (5–95 percentile, n ≥ 60 sister fork pairs pooled from 3 independent experiments, Mann-Whitney).

(C) Boxplot of CldU/IdU tract ratios of HeLa WT and EXD2<sup>−/−</sup> cells treated with 1 mM HU. (5–95 percentile, n ≥ 300 tracts pooled from 3 independent experiments, Mann-Whitney).

(D) Boxplot of CldU/IdU tract ratios of HeLa WT and EXD2<sup>−/−</sup> cells (left panel) and quantification of the percentage of stalled forks (red only tracts) in HeLa WT and EXD2<sup>−/−</sup> cells (right panel). (5–95 percentile, n ≥ 300 tracts pooled from 3 independent experiments Mann-Whitney [left panel]; n = 3 independent experiments, t test [right panel]).
Quantification of the frequency of chromosomal aberrations from mitotic spreads from HeLa WT and \(R\)EXD2 nuclease dead (ND) mutant protein (5–95 percentile, \(n\)).

Perturbation to replication fork progression in mammalian cells induces a high frequency of fork reversal (Zeillweger et al., 2015). This process is controlled by the action of multiple fork remodelers, which promote efficient fork repair and restart. Unscheduled fork reversal, however, is toxic and results in pathological degradation of nascent DNA driving genome instability (Kolinjivadi et al., 2017b; Mijic et al., 2017; Neelsen and Lopes, 2015). We therefore wondered if fork degradation observed in \(EXD2^{-/-}\) cells could be due to its role in counteracting regression of stalled forks. We tested this hypothesis in several ways; first, we examined the impact of depleting the SMARCA1 fork remodeler on fork degradation in cells lacking EXD2. Strikingly, SMARCA1 knockdown suppressed resection of stressed forks in these cells (Figures 6A, 6B, and S3E). Second, fork reversal is counteracted by the action of the RECQ1 helicase, which is inhibited by PARP1 (Berti et al., 2013). We reasoned therefore, that inhibiting PARP1 should de-repress RECQ1 and increase its fork restoration activity (Berti et al., 2013; Margalef et al., 2018). In support of our hypothesis, treatment of EXD2-deficient cells with the PARP1 inhibitor olaparib abolished the resection phenotype of \(EXD2^{-/-}\) cells (Figures 6A and 6C). Unscheduled fork reversal coupled with fork degradation is a pathological process that inhibits replication fork restart. Therefore, if \(EXD2\) acts to limit fork regression, limiting reversal in \(EXD2^{-/-}\) cells should improve the recovery of stalled forks. In support of this hypothesis, this is exactly what we observe. Downregulating SMARCA1 or removing the PARP1-dependent inhibition of RECQ1 restores the ability of \(EXD2^{-/-}\) cells to resume DNA synthesis, and importantly, ameliorates the genome instability of these cells (Figures 6D, 6E, and S4A–S4C). Contrary to this, silencing of RECQ1 is epistatic with \(EXD2\) deficiency suggesting that these two proteins function within the same mechanism to counteract fork regression (Figures S5A–S5D, and S5E [model]). However, because \(PARP1\) plays multiple roles in protecting stalled forks, including the recruitment of MRE11 to promote HR-dependent fork restart (Bryant et al., 2009), we considered the possibility that inhibiting fork resection alone may be enough to rescue fork restart in \(EXD2^{-/-}\) cells. Importantly, this is not the case as treatment with mirin, which inhibits over-resection in \(EXD2^{-/-}\) cells, does not rescue the defective fork restart (Figure S5E). To further support this hypothesis, we analyzed PARP1 recruitment to nascent DNA using the PLA assay. We reasoned that because PARP1-catalyzed PARylation of RECQ1 at stalled replication forks regulates its activity (Berti et al., 2013), PARP1 accumulation on nascent DNA could serve as an indirect readout of fork regression (Margalef et al., 2018). In support of our hypothesis, we see a significant increase in the PLA signal for PARP1-EdU in cells lacking EXD2 as compared to control. Crucially, this is rescued by the knockdown of SMARCA1 confirming that the PLA signal is derived from regressed forks (Figures 6F and S5F).

Reversal replication forks are predicted to arise via the translocation of the branch point of a stalled fork, followed by annealing of the two newly synthesized strands to create a 4-way junction. We hypothesized that EXD2-dependent nucleolytic processing of the regressed nascent strand(s) could counteract fork reversal. We therefore analyzed the ability of purified EXD2 to process structures mimicking reversed replication forks, including those with extruded nascent strands. Consistent with our hypothesis, EXD2 was able to degrade these substrates (Figures 6G and S6A–S6C). Collectively, these results support the conclusion that EXD2 nuclease-dependent fork processing counteracts fork regression and promotes restoration of active replication forks.

**EXD2 Depletion Is Synthetic Lethal with BRCA1/2**

Our analysis thus far suggested that EXD2 suppresses replication stress via a mechanism that is distinct from the role of the BRCA1/2 genes in this process. We therefore considered the possibility that EXD2 is required to avert replication catastrophe in cells lacking BRCA1/2. With this in mind, we first analyzed the proliferative capabilities of both single and double mutants. Strikingly, combined depletion of EXD2 with BRCA1/2 in HeLa or U2OS cells leads to an almost complete inhibition of cell growth (Figures 7A–7C and S6D–S6F). Importantly, this phenotype could be recapitulated in BRCA1/2-deficient cancer cell lines (Dran et al., 2017) (Figures 7D, 7E, S6G, and S6H) and is dependent on the nuclease activity of EXD2 (Figures 7F and S6I). To further our understanding of this synergistic interaction, we analyzed the frequency of micronuclei formation, as a readout of chromosomal instability. Consistent with the growth inhibition data, we noticed a marked increase in micronuclei formation in the double deficient mutants as compared to the singles (Figure 7G).

Surprisingly, we were unable to detect a significant increase in fork stalling or degradation in these double mutants (Figures S7A and S7B). Intriguingly, however, we noticed a dramatic deficiency of \(EXD2^{-/-}\) cells to generate chromosome end-to-end fusions (Figure S7C), which are dependent on the alternative end-joining pathway (Alt-EJ) (Mateos-Gomez et al., 2015). This pathway relies on limited resection of DSBs by the MRE11 nuclease to generate short stretches of homology used to bridge the break (Howard et al., 2015), and recent work has implicated Alt-EJ in survival of BRCA1/2-deficient tumors (Ceccaldi et al., 2016).
Figure 4. Loss of EXD2 Leads to Mitotic Abnormalities Associated with Under-Replicated DNA
(A) Quantification of the HeLa WT and EXD2<sup>ΔΔ</sup> anaphase or telophase cells showing DAPI-positive bridges (mean ± SEM, n = 3 independent experiments, chi-square). Scale bar, 10 μm.
(B) Quantification of HeLa WT and EXD2<sup>ΔΔ</sup>/C0 cells with 53BP1 OPT domains in G1 cells (left panel). Quantification of the number of 53BP1 OPT domains per positive cell in HeLa WT and EXD2<sup>ΔΔ</sup>/C0 cells (right panel) and representative images (mean ± SEM, n = 3 independent experiments, chi-square). Scale bar, 20 μm.
(C) Quantification of HeLa WT and EXD2<sup>ΔΔ</sup> cells showing MN and representative images. Phalloidin acts as a cytosolic marker (mean ± SEM, n = 3 independent experiments, chi-square). Scale bar, 20 μm.
(D) Quantification of HeLa WT, EXD2<sup>ΔΔ</sup>, and EXD2<sup>ΔΔ</sup> cells complemented with either Flag-EXD2 WT or Flag-EXD2 nuclease dead (ND) mutant protein for anaphase or telophase cells showing DAPI-positive bridges (mean ± SEM, n = 3 independent experiments, chi-square).
(E) Quantification of HeLa WT, EXD2<sup>ΔΔ</sup>, and EXD2<sup>ΔΔ</sup> cells complemented with either Flag-EXD2 WT or Flag-EXD2 nuclease dead (ND) mutant protein for cells showing MN (mean ± SEM, n = 3 independent experiments, chi-square).
Because EXD2 functionally interacts with the MRE11 nuclease (Broderick et al., 2016), we considered the possibility that the synthetic growth defect may reflect a lack of fork protection coupled with the loss of Alt-EJ to rescue unprotected forks. To test this, we depleted EXD2 in a U2OS cell line expressing the Alt-EJ reporter construct (Gunn et al., 2011), using BRCA2 and MRE11 knockdown as a positive and negative control, respectively. As previously reported, silencing of BRCA2 increased the level of Alt-EJ events whereas knockdown of MRE11 reduced its efficiency (Ceccaldi et al., 2015; Howard et al., 2015). Strikingly, we noticed that Alt-EJ was also significantly impaired in the absence of EXD2 (Figures 7H, S7D, and S7E). Collectively, these data suggest a role for EXD2 in promoting repair of chromosomal breaks in the absence of BRCA1/2 by an alternative end-joining pathway. Because Alt-EJ is essential for survival of BRCA1/2 mutants (Ceccaldi et al., 2015; Mateos-Gomez et al., 2015), we propose that combined depletion of BRCA1/2 and EXD2 results in an accumulation of broken replication forks, which cannot be rescued by the Alt-EJ backup mechanism driving mitotic catastrophe and cell death, even under normal growth conditions.

**DISCUSSION**

While addressing the key question of how cells maintain genome stability at stressed replication forks, we have determined that EXD2 is essential for an efficient response to replicative stress. We reveal that EXD2 is recruited to stalled forks with fast kinetics, similar to those observed for the MRE11 nuclease (Haince et al., 2008; Suhasini et al., 2013), and its loss compromises efficient replication fork progression. In line with this, EXD2<sup>−/−</sup> cells display sensitivity to a range of agents that interfere with DNA replication, including clinically relevant anti-cancer drugs. In keeping with EXD2’s role in mitigating replicative stress, EXD2 mutant cells enter mitosis...
A diagram illustrating the processes of fork reversal and fork restart in SMARCAL1 and RECQ1-mediated DNA repair.

B and C: Graphs showing the comparison of CdtU/Idu ratio with and without Olaparib treatment in HeLa cells with and without EXO2 deletion.

D and E: Box plots comparing fork restart (CdtU/Idu ratio) with and without Olaparib treatment in HeLa cells with and without EXO2 deletion.

F: Images of immunofluorescence staining with PLA: EdU/PARP1 and DAPI in HeLa cells with and without EXO2 deletion.

G: Gel electrophoresis results showing the fragmentation of DNA at different time points with and without Olaparib treatment.
with under-replicated DNA, which leads to elevated levels of anaphase bridges, G1-associated 53BP1 OPT domains, and micronuclei, likely all of which contribute to the increased chromosome breakage observed in these cells. Given the significant increase in 53BP1 foci (a marker of DSBs) in EXD2 \(-/\) cells during S-phase, we postulate that loss of EXD2 results in replication fork collapse.

Fork reversal has recently emerged as an important mechanism of cellular responses to replicative stress (Neelsen and Lopes, 2015). Uncontrolled fork reversal, however, can result in fork degradation, irreversible collapse, and genome instability (Kolinjivadi et al., 2017a; Pasero and Vindigni, 2017; Yeeyes et al., 2013). Surprisingly, we discovered that EXD2 acts at stressed forks to suppress their uncontrolled regression, most likely by enzymatically processing stalled forks to restrict their conversion to reversed forks. Our conclusion is supported by the following observation; inhibition of fork regression by down-regulation of SMARCAL1 or de-repressing PARP1-dependent inhibition of RECQ1 fork restoration activity rescues not only the excessive resection of stalled forks but also fork restart in EXD2 \(-/\) cells. Consistently, examining the association of PARP1 with nascent DNA indicates a significant increase in fork resection in the absence of EXD2, which is corrected by SMARCAL1 knockdown. Crucially, however, treatment with mirin, which inhibits fork resection in EXD2 \(-/\) cells, does not rescue fork restart. One model to explain how EXD2 functions in counteracting fork reversal is that large single-stranded DNA (ssDNA) gaps formed behind the stalled fork (Kolinjivadi et al., 2017b), and/or the already regressed nascent leading strand reveals a 3’ DNA end that can be acted upon by EXD2. Subsequently, nuclease processing of such a substrate alone, or together with the resection of the opposite nascent strand, may promote re-annealing of the parental strands and fork back-tracking (Pasero and Vindigni, 2017). A second model, which we favor, is that at the initial stage of fork regression, the nascent leading strand becomes dissociated (due to the spatial configuration of the fork, dissociated nascent strands may not be able to anneal with each other initially) or at the later stage, is actively displaced by RECQ1’s helicase activity, and subsequently, EXD2-dependent resection of the unpaired strand would prevent fork reversal (i.e., formation of a 4-way junction). In turn, this would shift the balance toward restoration of an active fork.

Indeed, EXD2 and RECQ1 deficiencies are epistatic and purified EXD2 is capable of degrading 3’ ssDNA within a substrate mimicking reversed forks with an extruded (unpaired) nascent strand. This could be an important mechanism restricting undesirable regression of a fork before the lagging strand is fully mature and/or upon transient dissociation of the leading strand during replisome stalling. Because the two sister chromatids are physically linked at the replication fork, displacement of the leading nascent strand (i.e., due to a transient fork reversal) followed by RAD51 filament formation could initiate homology search, increasing ectopic HR-driven recombination, a considerable problem for highly repetitive genomes (Lambert et al., 2010; Mizuno et al., 2009, 2013). Of note, leading- and lagging-strand polymerases are not always coordinated, and ssDNA intermediates form even at active forks (Graham et al., 2017). Accordingly, processing of the dissociated nascent strands in bacteria and yeast has been shown to enable replication fork structures to be regenerated, limiting HR-dependent chromosomal rearrangements (Courcelle et al., 2003; Hu et al., 2012; Iraqui et al., 2012; Yeeyes et al., 2013).

Interestingly, it has been proposed that efficient recovery of stalled forks in mammalian cells may require the action of an as yet unidentified 3’-5’ nuclease (Kolinjivadi et al., 2017a; Pasero and Vindigni, 2017). Therefore, it is tempting to speculate that EXD2, itself a 3’-5’nuclease, could be this missing factor. Consistent with this, our analysis shows that EXD2’s nuclease activity is essential for its role in promoting recovery of stressed forks and suppression of replication-associated genome instability.

**EXD2 Is Synthetic Lethal with BRCA1/2**

Germline mutations in the BRCA1/BRCA2 genes account for up to 80% of familial breast and ovarian cancer cases (King et al., 2003; Prakash et al., 2015). In their absence, nascent DNA at the stalled fork is extensively degraded, likely contributing to BRCA1/2-associated genome instability and sensitivity to replication stress-inducing therapies (Cecaldi et al., 2015; Chaudhuri et al., 2016). Our observation that loss of EXD2 induces excessive fork degradation that is not coupled to impaired RAD51 or BRCA1 association with stalled forks prompted us to analyze the genetic interaction between BRCA1/2 and EXD2. Surprisingly, we discovered that combined deficiency in
A

Cell proliferation (ratio over day 0)

Days

0 1 2 3 4

D

Cell proliferation (ratio over day 0)

Days

0 1 2 3 4 5 6 7

G

Cells with micronuclei (%)

siluc silBRCA2

HeLa EXO2−/− cl.1 silCtrl

B

Cell proliferation (ratio over day 0)

Days

0 1 2 3 4 5 6 7

E

Cell proliferation (ratio over day 0)

Days

0 1 2 3 4 5

H

Alt-EJ efficiency (%)

siluc silEXO2 silBRCA1 silBRCA2

I

Fork degradation

Fork collapse

Genome instability

Cell survival

Fork reversal

Reversed fork processing

Genome stability

Cell survival

Fork stalling

Fork recovery via

Alt-EJ mechanism

BRCA1/2−/−

Genome instability

Cell death

Genome instability

Cell survival

(legend on next page)
these factors is incompatible with cell proliferation, even in the absence of any exogenous challenge. Therefore, unlike depletion of fork remodelers (Koljinjivadi et al., 2017b; Mijic et al., 2017; Taglialetela et al., 2017), loss of EXD2 aggravates genomic instability associated with BRCA1/2 deficiencies. Tumors deficient in one DNA repair pathway often rely on a compensatory mechanism to resolve the damage. Consistent with this notion, we show a role for EXD2 in promoting repair of DSBs via alternative end-joining (Alt-EJ). Thus, in the absence of both EXD2 and BRCA1/2 proteins, unprotected replication forks collapse and cannot be rescued by either canonical HR or the Alt-EJ backup mechanism, ultimately compromising cell viability.

In conclusion, we show that EXD2 promotes efficient genome duplication by counteracting regression of stalled forks (Figures 7l and S5G). Since replicative stress is one of the major drivers of tumorigenesis and aging (Flach et al., 2014; Gaillard et al., 2015; Halazonetis et al., 2008), this work provides an important insight into mechanisms protecting cells against acquisition of DNA damage. In addition, our results offer a potential therapeutic target for tumors with BRCA1/2 deficiency. In the longer term, it would be worthy to assess the penetrance of this phenotype in other HR-deficient cancers.

STAR METHODS

Detailed methods are provided in the online version of this paper and include the following:

- **KEY RESOURCES TABLE**
- **LEAD CONTACT AND MATERIALS AVAILABILITY**
- **EXPERIMENTAL MODEL AND SUBJECT DETAILS**
- **METHOD DETAILS**
  - Cell Lines Generation
  - Plasmids and Cloning
  - Immunoblotting
  - Cell Survival and Proliferation Assays
  - RNAi treatment
- **IMMUNOFLOUORESCENCE MICROSCOPY**
  - EdU labeling of nascent DNA and Proximity Ligation Assay
  - iPOND
  - DNA fiber analysis
  - Protein Purification
  - In vitro nuclease assay

SUPPLEMENTAL INFORMATION

Supplemental Information can be found online at https://doi.org/10.1016/j.molcel.2019.05.026.

DECLARATION OF INTERESTS

W.N. is an inventor on a filed patent application covering targeting of EXD2 for cancer therapy.

Received: December 4, 2018
Revised: April 15, 2019
Accepted: May 17, 2019
Published: June 26, 2019

REFERENCES


## STAR★METHODS

### KEY RESOURCES TABLE

<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Antibodies</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>α-Tubulin</td>
<td>Sigma</td>
<td>T5168; RRID: AB_477579</td>
</tr>
<tr>
<td>BRCA1</td>
<td>Millipore</td>
<td>OP-92; RRID: AB_2750876</td>
</tr>
<tr>
<td>BRCA2</td>
<td>Millipore</td>
<td>OP-95; RRID: AB_2067762</td>
</tr>
<tr>
<td>EXD2</td>
<td>Sigma-Aldrich</td>
<td>HPA005848; RRID: AB_1078768</td>
</tr>
<tr>
<td>MCM2</td>
<td>Abcam</td>
<td>ab4461; RRID: AB_304470</td>
</tr>
<tr>
<td>MRE11</td>
<td>Abcam</td>
<td>ab214; RRID: AB_302859</td>
</tr>
<tr>
<td>PCNA</td>
<td>Santa-Cruz</td>
<td>PC-10; RRID: AB_628110</td>
</tr>
<tr>
<td>RECQ1</td>
<td>Santa-Cruz</td>
<td>SC-166388; RRID: AB_2178425</td>
</tr>
<tr>
<td>SMARCAL1</td>
<td>Santa-Cruz</td>
<td>Sc-376377; RRID: AB_10987841</td>
</tr>
<tr>
<td>53BP1</td>
<td>Millipore</td>
<td>MAB3802; RRID: AB_2206767</td>
</tr>
<tr>
<td>Cyclin A</td>
<td>Santa-Cruz</td>
<td>sc751; RRID: AB_631329</td>
</tr>
<tr>
<td>Biotin</td>
<td>Bethyl Laboratories,</td>
<td>A150-109A; RRID: AB_67327</td>
</tr>
<tr>
<td>Biotin</td>
<td>Jackson Immunoresearch</td>
<td>200-002-211; RRID: AB_2339006</td>
</tr>
<tr>
<td>BRCA1</td>
<td>Santa-Cruz</td>
<td>sc6954; RRID: AB_626761</td>
</tr>
<tr>
<td>Donkey anti-Mouse IgG (H+L) Secondary Antibody, Alexa Fluor 555</td>
<td>Thermo Fisher Scientific</td>
<td>A31570; RRID: AB_2536180</td>
</tr>
<tr>
<td>Donkey Anti-Rabbit IgG (H+L) Antibody, Alexa Fluor 488 Conjugated</td>
<td>Thermo Fisher Scientific</td>
<td>A21206; RRID: AB_141708</td>
</tr>
<tr>
<td>Anti-BrdU antibody; Rat monoclonal [BU1/75 (ICR1)]</td>
<td>Abcam</td>
<td>ab6326; RRID: AB_305426</td>
</tr>
<tr>
<td>Purified Mouse Anti-BrdU Clone B44</td>
<td>BD Biosciences</td>
<td>347580; RRID: AB_400326</td>
</tr>
<tr>
<td>Sheep anti-mouse Cy3 antibody</td>
<td>Sigma-Aldrich</td>
<td>C2181; RRID: AB_258785</td>
</tr>
<tr>
<td>Goat anti-Rat IgG (H+L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 488</td>
<td>Thermo Fisher Scientific</td>
<td>A11006; RRID: AB_2534074</td>
</tr>
<tr>
<td><strong>Chemicals, Peptides, and Recombinant Proteins</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PreScission Protease</td>
<td>GEHealthcare</td>
<td>27084301</td>
</tr>
<tr>
<td>Hydroxyurea</td>
<td>Sigma-Aldrich</td>
<td>H8627</td>
</tr>
<tr>
<td>Gemcitabine hydrochloride</td>
<td>Sigma-Aldrich</td>
<td>G6423-10MG</td>
</tr>
<tr>
<td>5-iodo-2'-deoxyuridine</td>
<td>Sigma-Aldrich</td>
<td>I7125</td>
</tr>
<tr>
<td>5-Chloro-2'-deoxyuridine</td>
<td>MP Biomedicals</td>
<td>105478</td>
</tr>
<tr>
<td>Mitomycin C</td>
<td>Sigma-Aldrich</td>
<td>M4287</td>
</tr>
<tr>
<td>Cis-diamineplatinum dichloride</td>
<td>Sigma-Aldrich</td>
<td>P4394</td>
</tr>
<tr>
<td>Mirin</td>
<td>Sigma-Aldrich</td>
<td>M9948</td>
</tr>
<tr>
<td>Olaparib AZD2281</td>
<td>Select Chem</td>
<td>S1060</td>
</tr>
<tr>
<td>Lipopectamine 2000</td>
<td>Thermo Fisher Scientific</td>
<td>11668019</td>
</tr>
<tr>
<td>HiPerfect</td>
<td>QIAGEN</td>
<td>301707</td>
</tr>
<tr>
<td>Vectashield</td>
<td>Vector Lab</td>
<td>H-1000</td>
</tr>
<tr>
<td>Vectashield with DAPI</td>
<td>Vector Lab</td>
<td>H-1200</td>
</tr>
<tr>
<td>Immobilon Western Chemiluminescent HRP substrate</td>
<td>Millipore</td>
<td>WBKLS0500</td>
</tr>
<tr>
<td><strong>Critical Commercial Assays</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Duolink® In Situ Red Starter Kit Mouse/Rabbit</td>
<td>Sigma-Aldrich</td>
<td>DUO92101-1KT</td>
</tr>
<tr>
<td>Invitrogen Molecular Probes Click-iT EdU Imaging Kit with Alexa Fluor 488, 594, and 647 Azides</td>
<td>Fischer Scientific</td>
<td>13435356</td>
</tr>
<tr>
<td>Biotin-dPEG&lt;sub&gt;7&lt;/sub&gt;-azide</td>
<td>Quanta Biodesign/ Stratech</td>
<td>10825-QUA</td>
</tr>
<tr>
<td>EdU (5-ethyl-2'-deoxyuridine)</td>
<td>Thermo Fisher Scientific</td>
<td>E10187</td>
</tr>
</tbody>
</table>

(Continued on next page)
<table>
<thead>
<tr>
<th>REAGENT or RESOURCE</th>
<th>SOURCE</th>
<th>IDENTIFIER</th>
</tr>
</thead>
<tbody>
<tr>
<td>Deposited Data</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Raw image files</td>
<td>This study, Mendeley</td>
<td><a href="https://doi.org/10.17632/gbc75sg6c7.1">https://doi.org/10.17632/gbc75sg6c7.1</a></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Experimental Models: Cell Lines</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HeLa</td>
<td>From Fumiko Esashi Laboratory</td>
<td>N/A</td>
</tr>
<tr>
<td>HeLa S3</td>
<td>From Ian D. Hickson Laboratory</td>
<td>N/A</td>
</tr>
<tr>
<td>U2OS</td>
<td>From Fumiko Esashi Laboratory</td>
<td>N/A</td>
</tr>
<tr>
<td>RPE-1</td>
<td>From Andrew Blackford Laboratory</td>
<td>N/A</td>
</tr>
<tr>
<td>HEK293FT</td>
<td>From Grant Stewart Laboratory</td>
<td>N/A</td>
</tr>
<tr>
<td>SUM149</td>
<td>From Chris Lord Laboratory</td>
<td>Dréan et al., 2017</td>
</tr>
<tr>
<td>SUM149 revertant</td>
<td>From Chris Lord Laboratory</td>
<td>Dréan et al., 2017</td>
</tr>
<tr>
<td>DLD1</td>
<td>From Chris Lord Laboratory</td>
<td>Dréan et al., 2017</td>
</tr>
<tr>
<td>DLD1 BRCA2</td>
<td>From Chris Lord Laboratory</td>
<td>Dréan et al., 2017</td>
</tr>
<tr>
<td>HeLa EXD2 −/−</td>
<td>Wojciech Niedzwiedz Laboratory,</td>
<td>Broderick et al., 2016</td>
</tr>
<tr>
<td>U2OS EXD2 −/−</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>RPE1 EXD2 −/−</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>RPE1 EXD2 ND/ND</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>HeLa EXD2 −/−→ Flag-HA-EXD2 WT</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>HeLa EXD2 −/−→ Flag-HA-EXD2 ND</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>U2OS + GFP-EXD2</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>U2OS + EXD2-GFP</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oligonucleotides</td>
<td></td>
<td></td>
</tr>
<tr>
<td>gRNA1; GTCTAATTCACCTTCTTAAGCAA</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>gRNA2; GACTTGGGATTGACTGTGAGT</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>ssODN ND; AGGAGGCAAGTGGGATCAAAT</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>siBRCA1- ACCAUACAGCUUCAAAAUAA</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>siBRCA2 ON-TARGETplus SMART pool,</td>
<td>Dharmacon</td>
<td>L-003462-00-0005</td>
</tr>
<tr>
<td>siEXD2 – CAGAGGACCAGGUAUUUA</td>
<td>Dharmacon</td>
<td>Broderick et al., 2016</td>
</tr>
<tr>
<td>siEXD2-2 (ON-TARGETplus EXD2 siRNA)</td>
<td>Dharmacon</td>
<td>L-020899-00-0005</td>
</tr>
<tr>
<td>siEXD2 (3’ UTR) GAACAGGAGCUCAAAUUUA</td>
<td>Dharmacon</td>
<td>Broderick et al., 2016</td>
</tr>
<tr>
<td>siSMARCAL1 ON-TARGETplus SMARTpool</td>
<td>Dharmacon</td>
<td>L-013058-00-0005</td>
</tr>
<tr>
<td>siMRE11 GAGGGUACGUGUUCAGA</td>
<td>Dharmacon</td>
<td>Broderick et al., 2016</td>
</tr>
<tr>
<td>siRECO1 ON-TARGETplus SMARTpool</td>
<td>Dharmacon</td>
<td>L-013597-00-0005</td>
</tr>
<tr>
<td>siLuciferase GTACGCGGAATACTTCGA</td>
<td>Dharmacon</td>
<td>Broderick et al., 2016</td>
</tr>
<tr>
<td>ON-TARGETplus Non-targeting Pool</td>
<td>Dharmacon</td>
<td>D-00180-10-20</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Recombinant DNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>pGEX6-His-EXD2 K76-V564</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>EXD2-peGFPN2</td>
<td>This study</td>
<td>N/A</td>
</tr>
<tr>
<td>EXD2-pHAGE-N-Flag-HA</td>
<td>Broderick et al., 2016</td>
<td>N/A</td>
</tr>
<tr>
<td>EXD2-pDEST-peGFP</td>
<td>This Study</td>
<td>N/A</td>
</tr>
<tr>
<td>pCMV-I-Sce1</td>
<td>a kind gift from Dr. V. Macaulay</td>
<td>N/A</td>
</tr>
<tr>
<td>pmCherry-C1</td>
<td>Clontech</td>
<td>N/A</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Software and Algorithms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>GraphPad Prism v7.00</td>
<td>GraphPad Software, La Jolla California USA</td>
<td><a href="https://graphpad.com">https://graphpad.com</a></td>
</tr>
</tbody>
</table>
LEAD CONTACT AND MATERIALS AVAILABILITY

Further information and requests for resources and reagents should be directed to the Lead Contact, Wojciech Niedzwiedz (wojciech.niedzwiedz@icr.ac.uk).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

HeLa and U2OS cells were a generous gift from Dr F. Esashi and were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and standard antibiotics. HEK293FT cells and HeLa S3 cells were a generous gift from Dr G. Stewart and Prof. I.D. Hickson, respectively, and were cultured in DMEM supplemented with 10% FBS and standard antibiotics. U2OS cells stably expressing GFP-CtIP were a generous gift from Prof. S.P. Jackson and were cultured in media supplemented with 500μg/ml G-418. U2OS EJ2-GFP cells were a kind gift of Prof. J. Stark. DLD1 WT and DLD1 BRCA2Δ/CΔ cell lines were a kind gift from Prof. C. Lord and were maintained in RPMI media supplemented with 10% fetal bovine serum, 5μg/ml insulin, and 1μg/ml hydrocortisone. U2OS cells stably expressing FLAG-HA EXD2 (generated previously) were cultured in DMEM supplemented with 0.5μg/ml Puromycin (GIBCO).

METHOD DETAILS

Cell Lines Generation
Cell lines stably expressing GFP EXD2 WT fusion proteins were generated by transfection of U2OS cells with this plasmid construct followed by clonal selection of cells grown in media containing 500μg/ml G418 (Life Technologies). HeLa EXD2Δ/CΔ cell lines stably expressing FLAG-HA EXD2 WT or D108A/E110A fusion proteins were generated by transfection of these cells with plasmid construct followed by clonal selection of cells grown in media containing 0.25μg/ml Puromycin (GIBCO).

U2OS and RPE1 EXD2Δ/CΔ cells were generated as previously described (Broderick et al., 2016). RPE1 EXD2ND/ND (D108A/E110A) were generated using following gRNAs GTCTAATTCACTTCTAAGCAA and GACTTGGAAATTGACTGTGAGT cloned into pAIO-NK vector (a kind gift from Dr. A. Blackford) and ssODN AGGAGGCAGAGTGGGATCAAATCGAGCCCTTGCTTAGATCTGAATTAGAAGTTTTCCAGTACTTGGATCGCTTTGTCGGTTAAGTTAAAAAGCAAAAGTTAAAAAA.

Plasmids and Cloning
Plasmid constructs employed to generate cell lines stably expressing FLAG EXD2 WT and FLAG EXD2 D108A/E110A were as previously described (Broderick et al., 2016). Plasmids expressing GFP-EXD2 were generated by cloning EXD2 into the pDEST-peGFP (a generous gift from Prof C. Green) or the peGFPN2 plasmid (Clontech). Plasmids were transfected into human cells using Lipofectamine 2000 (Life Technologies), according to the manufacturer’s instructions. GST-His-EXD2 K76-V564 construct was obtained by cloning His-EXD2 K76-564 (Broderick et al., 2016) into the pGEX-6P1 vector. The pCMV-I-SceI plasmid was a kind gift from Dr V. Macaulay. pmCherry-C1 was obtained from Clontech.

Immunoblotting
Cell lysis was carried out in urea buffer (9 M urea, 50 mM Tris HCL, pH 7.3, 150 mM j-mercaptoethanol) followed by sonication using a soniprep 150 (MSE) probe sonicator. In some instances, cells were lysed in SDS loading buffer (2% SDS, 10% (v/v) glycerol, 2% -Mercaptoethanol and 62.5 mM Tris-HCL, pH 6.8) followed by boiling for 10 min. Samples were resolved by SDS-PAGE and transferred to PVDF or nitrocellulose. Protein concentrations were determined by Bradford assay by spectrophotometry using a NanoDrop 2000 device (Thermo Scientific). Immunoblots were carried out using the indicated antibodies: α-Tubulin (Sigma, B-5-1-2; T5168, 1:100,000), BRCA1 (Millipore, OP-92, 1:1000), BRCA2 (Millipore, OP-95, 1:1000), EXD2 (Sigma, HPA005848, 1:1000), MCM2 (Abcam, ab4461, 1:10,000), MRE11 (Abcam, ab214, 1:1000), PCNA (Santa-Cruz, PC-10, 1:500), RECQ1 (Santa Cruz, sc-166388, 1:1000) and SMARCAL1 (Santa Cruz, sc-376377 1:1000).

Cell Survival and Proliferation Assays
Alamar Blue survival assays were performed in accordance with the manufacturer’s recommendations (Life Technologies). Briefly, 500 cells per well in 96-well plates were untreated or treated with indicated doses of camptothecin or ionising radiation and incubated for 7 days. Alamar blue reagent (Life Technologies) was added to each well and fluorometric measurements taken after 2h incubation at 37°C. For proliferation assays cells were seeded at 500 cells per well and Alamar blue reagent added and measurements taken each day as indicated.

RNAi treatment
siRNAs employed were as follows, siBRCA1: ACCAUACACGUUCUAAAUAA, siBRCA2 (ON-TARGETplus SMART pool L-003462-00-0005, Dharmacon.), siEXD2: CAGAGGACGCAGUAUAUUA, siMRE11: GAGAGUACUGCUUUCAGA, siRECO1 (ON-TARGETplus SMARTpool L-013597-00-0005) siSMARCAL1 (ON-TARGETplus SMARTpool L-013058-00-0005). ON-TARGETplus
Non-targeting Pool (D-00180-10-20, Dharmacon), or siRNA targeting luciferase - CGTACGCGAATACTTCTCGA were used as control siRNAs where appropriate. Oligonucleotides were transfected using HiPerfect reagent (QIAGEN), according to the manufacturer’s protocol.

**IMMUNOFLUORESCENCE MICROSCOPY**

For visualization of 53BP1 foci and OPT domains in Cyclin A-negative and -positive cells, respectively, cells were fixed with 4% paraformaldehyde in PBS for 10 min at room temperature, washed twice in PBS and permeabilised with 0.2% Triton X-100 in PBS for 10 min at room temperature. Coverslips were washed 3 x in PBS and blocked in 10% FBS in PBS for 30 min before incubation with primary antibodies in 0.1% FBS in PBS for 1 hour at room temperature, washed 4 x 5 min in PBS temperature followed by incubation with secondary antibodies for 45 min. Slides were then washed 4 x 5 min in PBS and mounted with Vectashield mounting medium (Vector Laboratories) with DAPI. Antibodies employed for immunofluorescence were as follows: 53BP1 (MAB3802, Millipore, 1:1000), Cyclin A (sc751, Santa Cruz, 1:100).

For Phalloidin staining, cells were fixed and permeabilised as above and incubated with PBS containing Alexa Fluor 647- Phalloidin (Thermo Fisher A22287, 1:50) before being mounted using Vectashield with DAPI.

For analysis of anaphase bridges cells were analyzed using a protocol adapted from Broderick et al. (2015). Briefly, cells were collected by mitotic shakeoff and spun onto poly-L-Lysine coated slides at 1000 x g for 3 min. Mitotic cells were then fixed using 4% PFA in PBS for 10 min at room temperature and mounted with Vectashield containing DAPI. Images were acquired using a Zeiss LSM 710 laser scanning confocal microscope with Zen software using a 63x objective. Image analysis was carried out with FIJI (ImageJ) software.

**EdU labeling of nascent DNA and Proximity Ligation Assay**

The association of proteins to newly synthesized DNA using EdU labeling and the Proximity Ligation Assay was carried out as previously described (Taglialatela et al., 2017). Briefly, U2OS cells or U2OS cells stably expressing GFP or FLAG-HA EXD2 were grown on coverslips before being labeled with 10 μM EdU for 10 min followed in some cases by treatment with 4mM hydroxyurea for various amounts of time as indicated.

Cells were then permeabilized using 0.5% Triton in PBS for 10 min at 4°C, washed twice in PBS and fixed with 3% formaldehyde, 2% sucrose in PBS for 10 min at room temperature. Post-fixation, cells were washed twice PBS and incubated with blocking solution (3% BSA in PBS) for 30 min. Slides were washed twice with PBS before conjugation of Biotin Azide to the newly incorporated EdU by click chemistry using the Click-iT reaction. The Click-iT reaction was carried out using a Click-iT assay kit (Thermo Fisher) according to the manufacturer’s instructions using 20 μM biotin-azide for 30 min. Coverslips were washed twice with PBS before incubation with the indicated primary antibodies for 1 hour at room temperature in 1% BSA/0.1% saponin in PBS.

Following primary antibody incubation coverslips were washed twice in PBS and then the proximity ligation assay was carried out using the Duolink In Situ Red Starter kit (Sigma Aldrich) according to the manufacturer’s instructions. Coverslips were mounted using Vectashield containing DAPI. For the PLA assay between GFP-EXD2 and BRCA1, cells were treated with HU for the indicated time before fixation in methanol at −20°C for 20 min followed by 3 washes with PBS. Blocking, primary antibody incubation and the PLA assay were then carried out as described above. Antibodies employed for the PLA assay were as follows: Biotin (Bethyl Laboratories, A150-109A, 1:3000), Biotin (Jackson ImmunoResearch, 200-002-211, 1:1000), BRCA1 (Santa Cruz, sc6954, 1:500), FLAG (Sigma, M2, 1:500), (GFP (Abcam, ab290, 1:500), GFP (Roche, 11 814 460 001, 1:500), MRE11 (Abcam, ab214, 1:100), PARP1 (Santa Cruz, sc-5364, 1:500), Rad51 (Calbiochem, PC130, 1:500). Images were acquired using a Zeiss LSM 710 laser scanning confocal microscope with Zen software using a 63x objective. Image analysis was carried out with FIJI (ImageJ) software.

**iPOND**

Logarithmically growing HeLa S3 cells (1 × 10⁸ per ml) or HEK293FT cells were incubated with 10 μM EdU for 10 minutes. Following EdU labeling, cells were fixed in 1% formaldehyde, quenched by adding glycine to a final concentration of 0.125 M and washed three times in PBS. Collected cell pellets were frozen at −80°C and cells were permeabilized by resuspending 1.0–1.5 × 10⁷ cells per ml in ice cold 0.25% Triton X-100 in PBS and incubating for 30 minutes. Before the Click reaction, samples were washed once in PBS containing 0.5% BSA and once in PBS. Cells were incubated for 1 hour at room temperature in Click reaction buffer containing 10 μM azide-PEG(3-3)-S-S-biotin conjugate (Click ChemistryTools, cat. no AZ112-25), 10 mM sodium ascorbate, and 1.5 mM copper (II) sulfate (CuSO4) in PBS. The ‘no Click’ reaction contained DMSO instead of biotin-azide. Following the Click reaction, cells were washed once in PBS containing 0.5% BSA and once in PBS. Cells were resuspended in lysis buffer (50 mM Tris–HCl pH 8.0, 1% SDS) containing protease inhibitor cocktail (Sigma) and sonicated with a Diagenode Bioruptor® Plus for 40 cycles (30 s on/30 s off). Samples were centrifuged at 14,500 rcf. at 4°C for 30 minutes and the supernatant was diluted 1:3 with TNT buffer (50 mM Tris pH 7.5, 200 mM NaCl and 0.3% Triton X-100) containing protease inhibitors. An aliquot was taken as an input sample. Streptavidin–agarose beads (Novagen) were washed three times in TNT buffer containing protease inhibitor cocktail. Two hundred microliters of bead slurry was used per 1 × 10⁸ cells. The streptavidin–agarose beads were resuspended 1:1 in TNT buffer containing protease inhibitors and added to the samples, which were then incubated at 4°C for 16 hours in the dark. Following binding, the beads were then washed two times with 1 mL TNT buffer, two times with TNT buffer containing 1M NaCl, two times with TNT buffer and
protein–DNA complexes were eluted by incubating with 5 mM DTT in TNT buffer. Cross-links were reversed by incubating samples in SDS sample buffer at 95°C for 20 minutes. Proteins were resolved on SDS-PAGE and detected by immunoblotting using specific antibodies.

**DNA fiber analysis**

DNA fiber assay was performed as described previously with some modifications (Schwab et al., 2015). In brief, exponentially growing cells were first incubated with 25 μM iododeoxyuridine (IdU) and then with 125 μM chlorodeoxyuridine (CldU) for the indicated times. Fiber spreads were prepared from 0.5 x 10^6 cells/ml. Slides were stained as described previously. A confocal microscope (LSM 510 Meta or LSM 710 Meta; Carl Zeiss) equipped with Plan-Apochromat 63×1.40 DIC objective was used to collect fiber images from randomly selected fields at RT using ZEN 2009 software (Carl Zeiss). Analysis was performed using the ImageJ software package (National Institutes of Health). A minimum of 100 fibers or 20 sister fork pairs per experiment from at least three independent experiments was scored. Mann-Whitney test was used to determine statistical significance. On boxplots whiskers indicate 5–95 percentile.

**Protein Purification**

GST-EXD2 K76-V564 was purified as described previously with some modifications. Briefly, GST protein expression was induced with 0.1 mM IPTG (isopropyl-β-d-thiogalactopyranoside) (Sigma-Aldrich) at 16°C for 18 hours. Bacteria were harvested by centrifugation and resuspended in lysis buffer containing 50 mM phosphate pH 8.0, 300mM NaCl, 1 mM DTT, 1% Triton X-100, 10 mM imidazol and PMSF. Lysates were sonicated and cleared by centrifugation. Supernatants were incubated with Ni resin (QIAGEN) for 2 h with rotation at 4°C. Beads were washed with lysis buffer containing 20 mM imidazol, and eluted with lysis buffer containing 300 mM imidazol. Eluates were then incubated with Glutathione HiCap Matrix (QIAGEN) for 2 h with rotation at 4°C. Beads were washed with increasing concentration of NaCl, elution buffer (50 mM Tris-HCl pH 7.0, 150 mM NaCl, 1 mM EDTA, 1 mM DTT, 0.2% Triton X-100) and resuspended in elution buffer supplemented with PreScission Protease (50 units/ml) (GE Healthcare) and incubated for 18 h with rotation at 4°C. Eluates were dialysed to buffer containing 20 mM HEPES-KOH pH7.2, 100 mM NaCl, 1 mM DTT, 10% glycerol, aliquoted and stored at −80°C.

**In vitro nuclease assay**

Sequences of DNA oligos used are listed in Table S1. To generate 5’ end labeled substrates, the indicated ssDNA oligo was labeled using [γ-32P]dATP and PPK enzyme (New England Biolabs). To obtain fork substrates, ssDNA oligos (as indicated in Table S1) were mixed in an equimolar ratio and annealed by heating at 100°C for 5 min followed by gradual cooling to room temperature.

Exonuclease assays were performed as described. Briefly, reactions were carried out in a buffer containing 20 mM HEPES-KOH, pH 7.5, 50 mM KCl, 0.5 mM DTT, 10 mM MnCl₂, 0.05% Triton-X, 0.1 mg ml⁻¹ BSA, 5% glycerol, and EXD2 protein (25 nM unless stated otherwise) and initiated by adding substrate (3nM unless stated otherwise) and incubated at 37°C for the indicated amounts of time. Reactions were stopped by addition of EDTA to a final concentration of 20 mM and 1/5 volume of formamide. The samples were resolved on denaturing 15% or 20% polyacrylamide TBE-Urea gels. Gels were fixed, dried and visualized using a Typhoon FLA 9500 instrument (GE Healthcare).

**Recruitment of GFP-tagged proteins to laser localized DNA damage**

Cells were grown on glass bottomed culture dishes (MatTek™, 35 mm). Plates were placed in an environmental chamber maintained at 37°C, 5% CO₂, 80% humidity, mounted on the stage of a Nikon TE2000 spinning disk microscope. Cells were visualized with a Plan Fluor ×60/1.25 numerical aperture oil objective. The microscope was equipped with an SRS NL100 nitrogen laser-pumped dye laser (Photonics Instruments, St. Charles, IL). To introduce DNA damage a defined region of interest (ROI, 4 x 20 pixels, 0.16 μm/pixel) in an individual nucleus was exposed to the laser firing 3-ns pulses at 365 nm with a repetition rate of 10 Hz. The laser was controlled by Velocity-5 software (Improvision; PerkinElmer Life Sciences). The beam was oriented by galvanometer-driven displacers and fired randomly throughout the region until the entire region was exposed. Images were taken before targeting and at defined intervals after targeting to detect the GFP-tagged protein recruitment to the targeted stripe. Velocity Software was used to quantify the intensity of the GFP signal at the damage site and at an equivalent area in a non-targeted region of the nucleus (background). Graphs show [GFP Intensity at the stripe/ GFP intensity at non-targeted stripe in the same nucleus] as a function of time in arbitrary units. The average of at least 10 cells was graphed for each experiment. Error bars represent the standard deviation.

**Chromosomal aberrations analysis**

Sub-confluent cultures of HeLa WT and the of HeLa EXD2-/- cl.1 and cl.2 cells, grown in DMEM with 10% FBS (GIBCO-BRL) plus antibiotics, at 37°C, were exposed to DMF (Sigma), 20 μM Cisplatin (Sigma) diluted in DMF for 16 h or 4 Gy X-ray irradiation. Two hours before harvest, the cells were exposed to colcemid (0.1μg/ml) (GIBCO). Cells were harvested by trypsinization (GIBCO), resuspended in culture medium and then spun down (10 minutes at 1000 rpm). Supernatant was removed, and then 0.075 M KCl (Sigma) at room temperature was added drop by drop. For hypotonic treatment, cell suspensions were incubated for 20 minutes at room temperature, and then 1 mL of fixative 3:1 methanol (Applichem GmbH, Darmstadt, Germany)-acetic acid (Merck, Darmstadt, Germany) was added. Cells were re-centrifuged for 10 minutes at 1000 rpm, supernatant was removed, fixative was
added, and then re-centrifuged in fixative for another two times. Finally, chromosome preparations were dropped onto wet microscope slides and left to air-dry. For inverted DAPI chromosome banding staining, slides were mounted with 0.1μg/ml DAPI in Vectashield antifade medium (Vector Laboratories, Burlingame, CA). Images of chromosome spreads were captured using a x63 magnification lens on a fluorescent Axio-Imager Z1, Zeiss microscope, equipped with a MetaSystems charge-coupled device camera and the MetaSystems Isis software. Chromosome lesions were recorded as breaks per chromosome number, per metaphase, in 75 metaphase spreads per condition, pooled from 3 independent experiments.

Alt-EJ GFP reporter assay
48 hours after siRNA transfection, U2OS EJ2-GFP cells (Gunn et al., 2011) were transfected using Amaxa nucleofection with an I-SceI expression vector (pCMV-I-SceI) or a vector expressing mCherry fluorescent protein (pmCherry-C1). 72 hours after I-SceI transfection cells were harvested and analyzed by flow cytometry (BD LSR II). 2x10^4 cells were analyzed per experimental condition. Number of GFP-positive cells per 1000 mCherry-positive cells was determined using BD FACS DIVA software. The data were then related in each experiment to siControl treated sample set as 1. Statistical significance was determined with the Student’s t test.

QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical calculations were done using GraphPad Prism 7 (GraphPad Software Inc.). Unpaired Student’s t test, Chi square test or Mann Whitney test were used to determine statistical significance as indicated in the Figure Legends. Sample sizes are indicated in the Figure Legends.